Peay HL, Fischer R, Mange B, Paquin RS, Smith EC, Sadosky A, Russo L, Ricotti V, Rensch C, Morris C, Martin AS, Ganot A, Beaverson K, Mansfield C. Patients' and caregivers' maximum acceptable risk of death for non-curative gene therapy to treat Duchenne muscular dystrophy. Mol Genet Genomic Med. 2021 May;9(5):e1664. doi: 10.1002/mgg3.1664
Roosli M, Foraster M, Feychting M, Huss A. ASPHER's European list of core competences for the public health professional. Scand J Public Health. 2018 Nov 13;46(23 Suppl):1-52. doi: 10.1177/1403494818797072
Selimovic N, Rundqvist B, Kjork E, Viriden J, Twiss J, McKenna SP. Adaptation and validation of the cambridge pulmonary hypertension outcome review for Sweden. Scand J Public Health. 2012 Dec;40(8):777-83. doi: 10.1177/1403494812464445
Reau N, Hamzeh FM, Lentz E, Zhou X, Jensen D. Characterization of nonrapid virologic response patients infected with HCV genotype 1 who may relapse after standard therapy with peginterferon plus ribavirin. J Viral Hepat. 2012 Feb;19(2):94-102.
Hershey N, Cann CI, Rothman KJ. Reply: overcoming hurdles to epidemiologic research. E & HR. 1985 Mar;7(2):9. doi: 10.2307/3564146
Cann CI, Rothman KJ. IRBs and epidemiologic research: how inappropriate restrictions hamper studies. E & HR. 1984 Jul;6(4):5-7. doi: 10.2307/3564590